Additional file 4: Figure S3. of A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients
Petra Seibold
Peter Schmezer
Sabine Behrens
Kyriaki Michailidou
Manjeet Bolla
Qin Wang
Dieter Flesch-Janys
Heli Nevanlinna
Rainer Fagerholm
Kristiina Aittomäki
Carl Blomqvist
Sara Margolin
Arto Mannermaa
Vesa Kataja
Veli-Matti Kosma
Jaana Hartikainen
Diether Lambrechts
Hans Wildiers
Vessela Kristensen
Grethe AlnĂŚs
Silje Nord
Anne-Lise Borresen-Dale
Maartje Hooning
Antoinette Hollestelle
Agnes Jager
Caroline Seynaeve
Jingmei Li
Jianjun Liu
Keith Humphreys
Alison Dunning
Valerie Rhenius
Mitul Shah
Maria Kabisch
Diana Torres
Hans-Ulrich Ulmer
Ute Hamann
Joellen Schildkraut
Kristen Purrington
Fergus Couch
Per Hall
Paul Pharoah
Doug Easton
Marjanka Schmidt
Jenny Chang-Claude
Odilia Popanda
10.6084/m9.figshare.c.3629045_D2.v1
https://springernature.figshare.com/articles/journal_contribution/Additional_file_4_Figure_S3_of_A_polymorphism_in_the_base_excision_repair_gene_PARP2_is_associated_with_differential_prognosis_by_chemotherapy_among_postmenopausal_breast_cancer_patients/4417778
Meta-analysis across BCAC studies of XRCC1 and breast cancer prognosis. Forest plot of the combined hazard ratios and 95Â % confidence intervals for XRCC1 rs3213356 in the discovery MARIE study and the replication studies in Breast Cancer Association Consortium (BCAC) using fixed effect models, according to treatment, i.e. no chemotherapy (A), any type of chemotherapy (B), and anthracycline-based chemotherapy (C). The combined effects for the BCAC studies were also based on fixed effect models. (DOCX 1077 kb)
2015-12-16 05:00:00
Survival
Genetic variation
Chemotherapy
Radiotherapy
Anthracyclines